Oyster Point Pharma Announces Positive Results from Phase 2 Clinical Trial of the Company’s Investigational Treatment for Dry Eye Disease
PRINCETON, N.J.--(BUSINESS WIRE)--#AECOS--Oyster Point Pharma, Inc., today announced results from the PEARL study, a Phase 2b clinical trial evaluating the company’s novel therapy for the treatment of Dry Eye Disease (DED). The study met both sign and symptom primary endpoints by showing a statistically significant improvement in each compared to a vehicle control. Topline data from the study will be presented at the American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium in Deer Vall